Skip to main content
Erschienen in: BMC Women's Health 1/2023

Open Access 01.12.2023 | Research

Risk of uterine leiomyomata with menstrual and reproductive factors in premenopausal women: Korea nurses’ health study

verfasst von: Sihan Song, Soojin Park, Bo Mi Song, Jung Eun Lee, Chiyoung Cha, Hyun-Young Park

Erschienen in: BMC Women's Health | Ausgabe 1/2023

Abstract

Background

Uterine leiomyomata (UL) are benign smooth muscle tumors that may cause significant morbidity in women of reproductive age. This study aimed to investigate the relationship of menstrual and reproductive factors with the risk of UL in premenopausal women.

Methods

This prospective study included 7,360 premenopausal women aged 22–48 years who were part of the Korea Nurses’ Health Study. Information on the menstrual cycle and reproductive history was assessed between 2014 and 2016, and self-reported cases of UL were obtained through 2021. Cox proportional hazards models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs).

Results

During 32,072 person-years of follow-up, 447 incident cases of UL were reported. After adjusting for other risk factors, women with late age at menarche had a lower incidence of UL (≥ 16 vs. 12–13 years: HR 0.68; 95% CI 0.47–0.99; p for trend = 0.026). The risk of UL was inversely associated with current menstrual cycle length (≥ 40 or too irregular to estimate vs. 26–31 days: HR 0.40; 95% CI 0.24–0.66) and cycle length at ages 18–22 years (HR 0.45; 95% CI 0.31–0.67; p for trend < 0.001, each). Parous women had lower risk of UL than nulliparous women (HR 0.40; 95% CI 0.30–0.53) and women who were aged 29–30 years at first birth had a lower risk of UL than those who were aged ≤ 28 years at first birth (HR 0.58; 95% CI 0.34–0.98). There was no significant association of the number of births or breastfeeding with the risk of UL among parous women. Neither a history of infertility nor oral contraceptive use was associated with the risk of UL.

Conclusions

Our results suggest that age at menarche, menstrual cycle length, parity, and age at first birth are inversely associated with the risk of UL in premenopausal Korean women. Future studies are warranted to confirm the long-term effects of menstrual and reproductive factors on women’s health.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Background

Uterine leiomyomata (UL), also known as myomas or fibroids, are benign tumors arising from the smooth muscle cells of the uterus [1]. Clinical symptoms include menorrhagia, pelvic pain, infertility, and pregnancy complications; symptomatic UL are the most common indication for hysterectomy [1, 2]. Globally, the age-standardized incidence rate of UL has steadily increased from 225.67 to 241.18 per 100,000 women between 1990 and 2019, respectively [3]. The occurrence of UL in the general population is likely to be underestimated because it is often asymptomatic and diagnosed incidentally during examination or surgery [1]. In an ultrasound screening study, the rates of self-reported and newly diagnosed UL in premenopausal women in the US were 35% and 51%, respectively [4]. The incidence of UL increases with age until menopause, and African-Americans have a higher risk of UL than other ethnicities [46]. Although its etiology remains largely unknown, UL are thought to have a genetic basis and are influenced by hormones and growth factors [1, 7, 8]. Reproductive factors, including early menarche and nulliparity, are recognized UL risk factors, and lifestyle factors such as obesity and alcohol drinking are possible risk factors for UL [911]. According to a recent report from the National Health Insurance Service–National Sample Cohort (NHIS-NSC), the cumulative incidence from 2003 to 2013 was 12.2% in Korean women, and the increase in the annual incidence was higher in younger ages [12]. The prevalence of UL in Korean women was reported as 9.0% in a self-administered online survey of reproductive age women conducted in 2009 [13] and 37.5% in a pelvic ultrasound study of middle-aged women conducted between 2005 and 2008 [14]. Decreased age at menarche [15], birth rate [16], and increased health examination rate [17] may explain the increasing prevalence of UL in Korea. However, more prospective data are required to provide evidence for UL prevention and treatment.
Current evidence on the risk factors for UL is largely derived from African-American and White women [10, 11]. Given the inconsistent results of previous cross-sectional [13, 18] and case-control [1922] studies in Asian populations, prospective data are needed to investigate the potential role of reproductive factors in the UL etiology.
Therefore, in this prospective cohort study of female nurses in Korea, we aimed to provide evidence of the association between menstrual and reproductive factors and risk of UL in premenopausal women.

Methods

Study population

The Korea Nurses’ Health Study (KNHS) is an ongoing prospective study of female Korean nurses [23]. A total of 20,613 women aged 20–45 years completed their first online survey (Module 1) between July 2013 and November 2014. Information on demographics, lifestyle, reproductive factors, and disease history were collected in Module 1. Six online surveys (Modules 2–7) were subsequently opened to participants between March 2014 and September 2019, and participants continued to be followed up via annual questionnaires from Module 8, which started in October 2019. Several questions such as disease history and job status were repeated in the modules. A detailed description of this cohort has been published previously [23]. Information on menstrual characteristics, oral contraceptive use, and a recent gynecological examination was first collected in Module 3, which was opened in November 2014. In this study, we included women who completed Module 3 before the opening Module 5 (November 2016), to ensure sufficient follow-up time by Module 9 (April 2021). Furthermore, this study participants were restricted to premenopausal women because UL develop during the reproductive years and commonly regress after menopause [7].
The flowchart of participant selection in this study is shown in Fig. 1. Of the 10,026 women who completed Module 3 between 2014 and 2016, we excluded those who were diagnosed with UL (n = 1,019) or cancer (n = 287); had undergone hysterectomy (n = 147); or reported menopause (n = 43) or no periods (n = 6). Women with missing data on exclusion criteria (n = 14) or reproductive factors (n = 20) were also excluded. Furthermore, women who did not return the follow-up survey (n = 648) or those who returned the last follow-up survey within one year after completion of Module 3 (n = 562) were excluded, leaving 7,412 women followed up from 2014 to 2021. Similar reproductive characteristics were observed between the included women and dropouts (data not shown). We further excluded those with cases of UL (n = 52) that occurred within one year of follow-up to reduce the possibility of reverse causation. Finally, 7,360 premenopausal women aged 22–48 years at baseline were included in this study.

Exposure assessment and covariates

Participants were asked about their age at menarche, time to regular menstrual cycles, and menstrual cycle patterns. In this study, we categorized age at menarche as ≤ 11, 12–13, 14–15, and ≥ 16 years and time to regular menstrual cycles as ≤ 1, 2–4, and ≥ 5 years or always irregular. Questions on menstrual patterns included cycle regularity and length at baseline and in early adulthood (ages 18–22 years). We categorized menstrual cycle regularity as very regular, regular, usually regular, and always regular and cycle length as < 26, 26–31, 32–39, and ≥ 40 days or too irregular to estimate. Data on parity history (defined as the total number of live births: nulliparous, 1, 2, and ≥ 3), age at first birth, and total months of breastfeeding were collected in Module 1 and during follow-up modules. Participants were asked if they had tried to conceive for at least one year (history of infertility) and, if so, whether they had consulted a physician to seek help. Information on the use of oral contraceptives for at least two months and Pap smear screening in the past two years was also obtained.
Data on anthropometric measurements and lifestyle factors, including smoking status and alcohol drinking, were collected during the initial baseline survey. The body mass index (BMI) was calculated as body weight divided by height squared (kg/m2). BMI was categorized into four groups (< 18.5, 18.5–22.9, 23.0–24.9, ≥ 25 kg/m2) according to the World Health Organization Asia-Pacific guidelines [24]. Perceived stress was assessed using the 4-item perceived stress scale (score range 0–16, higher scores indicate greater stress) [25]. Data on occupational factors, including frequency of rotating night shifts and hours of standing work, were also collected. Data on blood pressure and antihypertensive medication use were collected in Module 3. Participants who reported the use of antihypertensive medications were asked to report their most recent blood pressure without medication. Systolic blood pressure (SBP) was categorized as < 105, 105–114, 115–124, 125–134, and ≥ 135 mmHg.

Outcome assessment and follow-up

In the follow-up surveys, participants were asked if they had been diagnosed with UL by a physician (Modules 4, 5, 7–9) and had undergone myomectomy (Modules 4, 5, 8, 9). Thus, the participants were asked to report their calendar year of diagnosis and/or surgery. Updated information on cancer diagnosis, hysterectomy, and menopausal status was also obtained from the follow-up questionnaires. The person-years were calculated from the date of return of Module 3 to the date of diagnosis of UL, cancer, hysterectomy, menopause, or last returned Module, whichever came first. The index date was defined as the midpoint of the calendar year. If the year of diagnosis, surgery, or menopause was the same as the survey year, the index date was defined as the midpoint of the survey date. 85% of the participants returned Module 8 or 9 during a median follow-up of 4.6 years.

Statistical analysis

Descriptive statistics are presented as median and interquartile range (IQR) or percentages. Cox proportional hazards models were used to estimate age- and multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of the associations between the reproductive factors of interest and UL risk. Multivariable models adjusted for age in years, age at menarche, menstrual cycle length, parity history, BMI, SBP, and a recent gynecological examination (Pap smear screening). Smoking, alcohol drinking, perceived stress, and occupational factors were not included in the final model, because these variables did not markedly change the estimates. P-values for the trend were calculated by assigning the median value (or mid-point) of each category of exposures in the model as a continuous variable. Associations of the number of births, age at first birth, and total duration of breastfeeding with UL risk were examined among parous women. The proportional hazard assumption was tested using time-dependent interaction terms, and no violation of this assumption was found. To explore the possibility of detection bias, all analyses were repeated in a subgroup of women who reported a recent gynecological examination (n = 2,924). Sensitivity analyses were performed by excluding women with a cycle length > 50 days or too irregular to estimate from the cycle length analyses and excluding those with a history of infertility from the parity analysis.
Statistical significance was defined as a two-sided p-value of < 0.05. All the analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).

Results

During the 32,072 person-years of follow up, 447 new cases of UL were reported with a cumulative incidence of 6.1%. Approximately 20% of incident cases underwent myomectomy or hysterectomy. For the 7,360 participants included in this analysis, the median age at baseline was 29 years (IQR, 26–35 years) (Table 1). About half of the women had menarche before age 14 years, 51% had ≤ 1 years to regular menstrual cycles, 76% had very regular or regular cycles, and 59% had menstrual cycle lengths of 26–31 days. The menstrual patterns in early adulthood were similar to the current patterns (data not shown). Overall, 31% of the women were parous (median age at first birth, 30 years); of these, 50% reported having breastfed for at least 6 months. 6% of the women reported that they had tried to conceive for at least one year, 7% reported oral contraceptive use for at least two months, and 40% had a Pap smear within the past two years.
Table 1
Baseline characteristics of study participants
Characteristics
N = 7,360
Age (median years, IQR)
29 (26–35)
Age at menarche, years (%)
 
  ≤ 11
4.9
  12–13
44.8
  14–15
40.8
  ≥ 16
9.5
Time to regularity, years (%)
 
  ≤ 1
51.0
  2–4
21.2
  ≥ 5 or always irregular
27.8
Menstrual cycle regularity (%)
 
  Very regular
31.6
  Regular
44.3
  Usually irregular
17.6
  Always irregular
6.5
Menstrual cycle length, days (%)
 
  < 26
9.1
  26–31
59.2
  32–39
23.2
  ≥ 40 or too irregular to estimate
8.5
Parous (%)
31.5
    Age at first birth (median years, IQR)
30 (28–32)
    Duration of breastfeeding, ≥ 6 months (%)
50.1
Attempting to conceive, ≥ 1 year (%)
5.8
Oral contraceptives use, ≥ 2 months (%)
6.7
    Age at first use (median years, IQR)
26 (24–29)
Pap spear screening within past 2 years (%)
39.7
Ever smokers (%)
2.6
Alcohol consumption, ≥ 1 drink/day (%)
7.6
Body mass index, kg/m2 (%)
 
  < 18.5
15.6
  18.5–22.9
66.7
  23–24.9
10.0
  ≥ 25
7.7
Perceived stress (scores, IQR)
7 (5–8)
Antihypertensive medication use (%)
0.5
Systolic blood pressure, mmHg (%)
 
  < 105
21.5
  105–114
41.4
  115–124
27.6
  125–134
7.9
  ≥ 135
1.6
Rotating night shift, nights/month (%)
 
  None
31.1
  < 7
36.8
  ≥ 7
32.1
On feet at work, hours/day (%)
 
  ≤ 4
33.4
  5–8
45.2
  ≥ 9
21.3
IQR, interquartile range (25th–75th percentile)
The risk of UL was inversely associated with age at menarche (Table 2). Compared with women aged 12–13 years at menarche, those aged 14–15 years (multivariable-adjusted HR 0.80; 95% CI 0.65–0.98) and ≥ 16 years at menarche (HR 0.68; 95% CI 0.47–0.98) had lower risks of UL (p for trend = 0.026). Time to regular cycles and regularity of current cycles were not associated with UL risk. However, irregular cycles in early adulthood were associated with a reduced risk of UL (always irregular vs. regular: HR, 0.61; 95% CI 0.39–0.97). Current and early adulthood cycle lengths were inversely associated with UL risk (p for trend < 0.001, respectively). Compared with women with a cycle length of 26–31 days, those with a cycle length of > 40 days or those with too irregular to estimate cycle lengths had a lower UL risk (HR 0.40; 95% CI 0.24–0.66). At ages 18–22 years, those with a cycle length of 32–39 days (HR 0.73; 95% CI 0.56–0.94) and ≥ 40 days or too irregular to estimate (HR 0.45; 95% CI 0.31–0.67) had lower risk of UL than those with a length of 26–31 days. Associations were robust when we restricted analyses to those who with a cycle length ≤ 50 days. The HRs (95% CIs) comparing cycle lengths of 40–50 with 26–31 days were 0.55 (0.30–1.00) for current and 0.42 (0.22–0.82) for early adulthood.
Table 2
Association between menstrual characteristics and risk of uterine leiomyomata
Characteristics (N = 7,360)
Person-years
Cases
Age-adjusted
HR (95% CI)
Multivariate
HR (96% CI)
Menarche age, years a
    
  ≤ 11
1547
22
0.96 (0.62–1.49)
0.96 (0.62–1.48)
  12–13
14,341
227
Reference
Reference
  14–15
13,178
165
0.75 (0.61–0.92)
0.80 (0.65–0.98)
  ≥ 16
3006
33
0.65 (0.45–0.94)
0.68 (0.47–0.99)
  P for trend
  
0.007
0.026
Time to regular cycles, yearsb
    
  ≤ 1
16,326
242
Reference
Reference
  2–4
6829
94
0.96 (0.75–1.21)
0.92 (0.72–1.17)
  ≥ 5 or always irregular
8916
111
0.89 (0.71–1.12)
0.87 (0.70–1.10)
  P for trend
  
0.341
0.253
Menstrual cycle regularityb
    
  Cycle regularity
    
    Very regular
9748
157
1.03 (0.84–1.27)
1.03 (0.84–1.27)
    Regular
13,669
202
Reference
Reference
    Usually irregular
5420
59
0.78 (0.58–1.04)
0.77 (0.57–1.03)
    Always irregular
1998
22
0.79 (0.51–1.23)
0.78 (0.50–1.21)
    P for trend
  
0.064
0.052
  Cycle regularity ages 18–22 years
    
    Very regular
8423
142
1.11 (0.90–1.37)
1.09 (0.88–1.35)
    Regular
14,890
214
Reference
Reference
    Usually irregular
6277
69
0.78 (0.60–1.03)
0.78 (0.59–1.02)
    Always irregular
2310
20
0.62 (0.39–0.97)
0.61 (0.39–0.97)
    P for trend
  
0.002
0.003
Menstrual cycle lengthb
    
  Cycle length, days
    
    < 26
2793
42
0.95 (0.69–1.32)
0.96 (0.69–1.32)
    26–31
18,224
291
Reference
Reference
    32–39
7154
91
0.85 (0.67–1.08)
0.85 (0.67–1.08)
    ≥ 40 or too irregular to estimate
2663
16
0.41 (0.25–0.68)
0.40 (0.24–0.66)
    P for trend
  
0.001
< 0.001
  Cycle length ages 18–22 years, days
    
    < 26
2700
38
0.92 (0.66–1.29)
0.91 (0.65–1.28)
    26–31
19,205
310
Reference
Reference
    32–39
6225
70
0.71 (0.55–0.92)
0.73 (0.56–0.94)
    ≥ 40 or too irregular to estimate
3775
27
0.45 (0.31–0.67)
0.45 (0.31–0.67)
    P for trend
  
< 0.001
< 0.001
aAdjusted for age at baseline, menstrual cycle length, parity history, body mass index, systolic blood pressure, and a recent gynecologic examination
bAdjusted for age at baseline, age at menarche, parity history, body mass index, systolic blood pressure, and a recent gynecologic examination
CI, confidence interval; HR, hazard ratio
Parous women had significantly lower risk of UL compared with nulliparous women (HR 0.40; 95% CI 0.30–0.53) (Table 3). This inverse association remained significant even after excluding women with a history of infertility (parous vs. nulliparous: HR, 0.38; 95% CI 0.29–0.51). Compared with women aged ≤ 28 years at first birth, those who were aged 29–30 at first birth had lower UL risk (HR 0.58; 95% CI 0.34–0.98). Among parous women, the number of births and total breastfeeding duration were not significantly associated with UL risk. No association was observed between either a history of infertility or oral contraceptive use and the risk of UL.
Table 3
Associations of reproductive history and oral contraceptive use with the risk of uterine leiomyomata
Characteristics (N = 7,360)
Person-years
Cases
Age-adjusted
HR (95% CI)
Multivariate
HR (96% CI)
Paritya
    
  Nulliparous
22,047
327
Reference
Reference
  Parous
10,025
120
0.44 (0.34–0.56)
0.40 (0.30–0.53)
    No. of births
    
      1
4214
37
Reference
Reference
      2
5184
74
1.10 (0.72–1.68)
1.10 (0.72–1.68)
      ≥ 3
626
9
1.06 (0.50–2.23)
1.17 (0.55–2.48)
      P for trend
  
0.737
0.625
    Age at first birth, years
    
      ≤ 28
3178
51
Reference
Reference
      29–30
2231
19
0.57 (0.33–0.96)
0.58 (0.34–0.98)
      ≥ 31
3217
37
0.69 (0.45–1.06)
0.67 (0.44–1.03)
      P for trend
  
0.113
0.086
    Total breastfeeding, months
    
      0
837
17
Reference
Reference
      1–5
3058
38
0.71 (0.40–1.26)
0.64 (0.36–1.14)
      6–11
1849
25
0.83 (0.45–1.56)
0.80 (0.42–1.50)
      ≥ 12
2169
23
0.69 (0.36–1.32)
0.63 (0.33–1.21)
      P for trend
  
0.472
0.415
Attempting to conceive (≥ 1 year)b
    
  No
30,186
428
Reference
Reference
  Yes
1886
19
0.62 (0.39–0.98)
0.70 (0.44–1.12)
    Consulting a physician
    
      No
957
9
Reference
Reference
      Yes
929
10
1.05 (0.42–2.59)
1.36 (0.52–3.54)
Oral contraceptive use (≥ 2 months)b
    
  No
29,874
422
Reference
Reference
  Yes
2195
25
0.88 (0.59–1.33)
0.98 (0.65–1.48)
    Age at first use, years
    
      ≤ 26
1323
15
Reference
Reference
      > 26
752
9
0.96 (0.34–2.72)
0.75 (0.25–2.25)
aAdjusted for age at baseline, age at menarche, menstrual cycle length, body mass index, systolic blood pressure, and a recent gynecologic examination
bAdjusted for age at baseline, age at menarche, menstrual cycle length, parity history, body mass index, systolic blood pressure, and a recent gynecologic examination
CI, confidence interval; HR, hazard ratio
When we restricted the analyses to those who had a recent gynecological examination, the inverse associations of age at menarche, cycle length in early adulthood, and parity with UL risk remained significant (Table 4).
Table 4
Association between selected menstrual and reproductive factors and uterine leiomyomata risk among women reporting recent gynecologic examination
Characteristics (N = 2,924)
Person-years
Cases
Age-adjusted
HR (95% CI)
Multivariate
HR (96% CI)
Menarche age, yearsa
    
  ≤ 11
568
11
1.16 (0.62–2.17)
1.19 (0.64–2.23)
  12–13
5445
99
Reference
Reference
  14–15
5498
69
0.65 (0.48–0.89)
0.70 (0.51–0.96)
  ≥ 16
1179
9
0.39 (0.20–0.77)
0.40 (0.20–0.79)
  P for trend
  
< 0.001
0.001
Menstrual cycle lengthb
    
  Cycle length, days
    
    < 26
910
19
1.25 (0.77–2.02)
1.26 (0.77–2.05)
    26–31
7271
120
Reference
Reference
    32–39
2672
39
0.94 (0.65–1.35)
0.91 (0.63–1.31)
    ≥ 40 or too irregular to estimate
948
7
0.49 (0.23–1.05)
0.48 (0.22–1.03)
    P for trend
  
0.04
0.03
  Cycle length ages 18–22 years, days
    
    < 26
788
12
0.91 (0.51–1.64)
0.92 (0.51–1.67)
    26–31
7933
138
Reference
Reference
    32–39
2420
25
0.61 (0.40–0.93)
0.62 (0.40–0.95)
    ≥ 40 or too irregular to estimate
1472
12
0.48 (0.27–0.87)
0.49 (0.27–0.89)
    P for trend
  
0.007
0.008
Parityc
    
  Nulliparous
5365
87
Reference
Reference
  Parous
7326
101
0.51 (0.35–0.73)
0.52 (0.36–0.76)
    Age at first birth, years
    
      ≤ 28
2253
41
Reference
Reference
      29–30
1607
16
0.61 (0.34–1.08)
0.62 (0.34–1.11)
      ≥ 31
2353
32
0.75 (0.47–1.19)
0.70 (0.44–1.12)
      P for trend
  
0.263
0.157
Attempting to conceive (≥ 1 year)d
    
  No
11,213
174
Reference
Reference
  Yes
1479
14
0.59 (0.34–1.01)
0.62 (0.36–1.08)
Oral contraceptive use (≥ 2 months)d
    
  No
11,631
178
Reference
Reference
  Yes
1057
10
0.69 (0.37–1.32)
0.76 (0.40–1.45)
aAdjusted for age at baseline, menstrual cycle length, parity history, body mass index, and systolic blood pressure
bAdjusted for age at baseline, age at menarche, parity history, body mass index, and systolic blood pressure
cAdjusted for age at baseline, age at menarche, menstrual cycle length, body mass index, and systolic blood pressure
dAdjusted for age at baseline, age at menarche, menstrual cycle length, parity history, body mass index, and systolic blood pressure
CI, confidence interval; HR, hazard ratio

Discussion

In this prospective study, we examined the association between reproductive factors and UL risk in premenopausal Korean women. We observed that the risk of UL was inversely associated with the age at menarche, menstrual cycle length, parity, and age at first birth. No associations were observed with either the number of birth, breastfeeding, history of infertility, or oral contraceptive use.
In this study, a later age at menarche was associated with a reduced risk of UL. Some cross-sectional [13, 18] or case-control studies [21, 22, 26] found no significant association between age at menarche and UL. However, two Korean case-control studies [21, 22] and one Japanese cross-sectional study [18] did not restrict the participants to women of reproductive age. Consistent with our study, epidemiologic studies conducted in the US suggest an inverse association between age at menarche and UL risk among premenopausal women [2732]. In the Nurses’ Health Study (NHS) II that included a large cohort of female nurses who were predominantly Caucasian, a significant inverse association between age at menarche and UL risk was observed. The relative risks of UL for women aged ≥ 16 versus 12 years at menarche were 0.68 and 0.77 in the 4-year and 14-year follow-up, respectively [27, 29]. Similarly, the Black Women’s Health Study (BWHS) observed a 30% lower risk of UL among African-American women aged ≥ 15 versus < 11 years at menarche during a 4-year follow-up [28]. Moreover, in the “Right From the Start” study, ultrasound examinations were performed during early pregnancy to systematically screen for UL, and an association was observed between early age at menarche and the presence and number of UL [32]. Although the biologic mechanisms are not fully understood, women at an early age of menarche may have increased menstrual cycling and lifetime exposure to estrogens, which are thought to promote the growth of UL [27, 28]. Furthermore, early life factors that cause early menarche may be linked to the development of UL in adulthood [33].
Mitotic activity in the myometrium is higher during the luteal phase of the menstrual cycle [34]; therefore, frequent menstrual cycles may contribute to myoma formation. In this study, women with a long cycle length at baseline and those with long and/or irregular cycles at ages 18–22 years were less likely to develop UL. Our findings are biologically plausible, given that menstrual cycle length decreases with age until menopause, as the length of the follicular phase shortens [35]. Although the relationship between menstrual patterns and UL risk is less clear, studies on female nurses in the US and Japan have shown results consistent with those of our study. Long and/or irregular cycles were significantly associated with a lower risk of UL in the NHS II [29], and long cycle length at ages 18–22 was inversely associated with the odds of UL in the Japan Nurses’ Health Study [18]. In an online survey across eight countries, women with UL were more likely to report frequent periods than those without UL [13]. However, no such association was observed in a US case-control study [30] and an Italian cross-sectional study [36]. Further investigations are needed to clarify the role of menstrual patterns in UL development.
The inverse association between parity and UL risk in this study is consistent with the results of previous studies [19, 22, 2729, 3739]. Compared with nulliparous women, the risk reduction of UL in parous women ranges from 30 to 60%, and several studies have shown a decreased UL risk with an increasing number of births [27, 29, 37, 38]. The risk of UL among parous women did not decrease with each additional birth in our study, and a similar finding was observed in the BWHS [28]. Two US studies reported a lower incidence of UL with a later age at first birth and shorter time since last birth [28, 29]. Although the age range at first birth in our study was narrow, we observed a similar relationship with UL risk. There are several hypotheses regarding the role of pregnancy and childbirth in the occurrence of UL, including hormonal changes during pregnancy [34, 40, 41] and after birth [42], decreased lifetime exposure to ovarian hormones [43], and postpartum uterine involution and remodeling [4446]. In NHS II, a risk reduction of UL was observed in women who breastfed for longer than 3 years, and this association may be partially explained by the postpartum amenorrhea [29]. However, consistent with our findings, no apparent association was observed between breastfeeding duration and UL risk in several studies [19, 26, 28].
In the present study, a history of infertility was not associated with the risk of UL. The presence of UL may be a cause rather than a consequence of infertility [33, 38]. Consistent with previous studies [27, 28], the inverse association with parity remained significant after excluding women with a history of infertility; therefore, reverse causation is unlikely to explain our results. Some studies have shown a reduced risk of UL in ever [19], current [27, 30, 47], and longer duration users of oral contraceptives [37, 47]. Most studies found no association between oral contraceptive use and UL risk [26, 28, 29, 31, 39, 48]. Decreased exposure to unopposed estrogen due to the modifying effect of exogenous progestogens has been proposed as a possible explanation [37]; however, the possibility remains that oral contraceptive use may delay the diagnosis of UL by reducing the symptoms, such as heavy menstrual bleeding [33]. Moreover, two studies reported that early initiation of oral contraceptives was associated with an increased risk of UL [27, 28]. In this study, ever use and age at first use of oral contraceptives were not associated with the risk of UL. However, further analyses are warranted to examine the role of the duration and formulation of oral contraceptives in UL development.
This study has several limitations. First, the data on reproductive factors and UL diagnosis were self-reported. Data on reproductive factors were collected before the diagnosis of UL; therefore, misclassification of exposures, including age at menarche and menstrual pattern, were likely non-differential. According to validation studies of self-reported UL in US cohorts, the positive predictive value ranged from 92 to 96% [5, 28, 49]. Although future validation is needed, the medical conditions reported by health professionals are more accurate than those reported by the general population. The cumulative incidence and proportion of UL treatment in our study were comparable to those in previous reports. In the NHIS-NSC, the cumulative incidence of UL over 5 years (2003–2007) was approximately 5%, and the treatment percentage of UL in 2013 was 15% [12]. Before excluding UL cases at baseline, the UL prevalence in our study participants (approximately 10%) was similar to that reported in a previous online survey conducted in 2009 (9%) [13]. Second, detection bias cannot be ruled out. Many UL cases are asymptomatic; however, the cases in this study are likely to be symptomatic because participants in the KNHS were not systemically screened for UL. Incidental detection of UL may be more likely in women with pregnancy, infertility, irregular cycles, and oral contraceptive use than in those without. However, given the inverse association between parity and UL risk, incidental detection is unlikely to explain our results and may attenuate this association. Robust results among women reporting a recent Pap smear screening also suggest that detection bias is unlikely. Third, there is a potential selection bias due to loss to follow-up, even though similar reproductive characteristics were observed between the women who were followed up and those who were not. Fourth, the small number of incident cases limits further analysis, and future confirmation with a larger number of cases is warranted. Fifth, there is a possibility of residual confounding; for example, data on family history of UL and time since last birth were not collected in this study. Finally, the generalizability of our findings to the entire reproductive-age population may be limited, because our population consisted of female nurses aged 22–48 years. However, given the consistency of our results with those of previous studies, there is no strong rationale for differences in the role of reproductive factors in UL development between this study population and women in the general population. Despite these limitations, this is the first longitudinal study to examine the relationship of menstrual cycles and reproductive factors with UL risk in premenopausal Korean women. The availability of information on menstrual patterns at two different points is another strength of our study.

Conclusions

Findings from this prospective study of female nurses suggest that later age at menarche, long menstrual cycles, long or irregular cycles in early adulthood, and parity are associated with a reduced risk of UL in premenopausal Korean women. The inverse associations of menstruation and parity with UL risk were robust among women reporting a recent gynecological exam. The incidence of UL did not differ according to history of infertility or oral contraceptive use. Our results support the hypothesis that endogenous hormones play a significant role in UL etiology. Further investigation is needed to confirm the long-term effects of menstrual and reproductive factors on UL and other gynecologic conditions.

Acknowledgements

We thank all the nurses who participated in the Korea Nurses’ Health Study and voluntarily completed the questionnaire.

Declarations

This study was approved by the Institutional Review Board of the Korea Disease Control and Prevention Agency (2013-03CON-03-P and 2021-04-02-2 C-A). All participants provided an electronic informed consent prior to participation. All methods were performed in accordance with relevant guidelines and regulations.
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Schuiling KD, Likis FE. Women’s gynecologic health. 2nd ed. United States/Burlington: Jones & Bartlett Learning; 2013. Schuiling KD, Likis FE. Women’s gynecologic health. 2nd ed. United States/Burlington: Jones & Bartlett Learning; 2013.
3.
Zurück zum Zitat Cheng L-C, Li H-Y, Gong Q-Q, Huang C-Y, Zhang C, Yan J-Z. Global, regional, and national burden of uterine fibroids in the last 30 years: estimates from the 1990 to 2019 global burden of Disease Study. Front Med (Lausanne). 2022;9:1003605.PubMedCrossRef Cheng L-C, Li H-Y, Gong Q-Q, Huang C-Y, Zhang C, Yan J-Z. Global, regional, and national burden of uterine fibroids in the last 30 years: estimates from the 1990 to 2019 global burden of Disease Study. Front Med (Lausanne). 2022;9:1003605.PubMedCrossRef
4.
Zurück zum Zitat Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188:100–7.CrossRef Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188:100–7.CrossRef
5.
Zurück zum Zitat Marshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE, Colditz GA, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997;90:967–73.PubMedCrossRef Marshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE, Colditz GA, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997;90:967–73.PubMedCrossRef
6.
Zurück zum Zitat Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril. 2007;87:725–36.PubMedCrossRef Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril. 2007;87:725–36.PubMedCrossRef
8.
Zurück zum Zitat Dixon D, Parrott EC, Segars JH, Olden K, Pinn VW. The second National Institutes of Health International Congress on advances in uterine leiomyoma research: conference summary and future recommendations. Fertil Steril. 2006;86:800–6.PubMedCrossRef Dixon D, Parrott EC, Segars JH, Olden K, Pinn VW. The second National Institutes of Health International Congress on advances in uterine leiomyoma research: conference summary and future recommendations. Fertil Steril. 2006;86:800–6.PubMedCrossRef
9.
Zurück zum Zitat Yang Q, Ciebiera M, Bariani MV, Ali M, Elkafas H, Boyer TG, et al. Comprehensive review of uterine fibroids: developmental origin, pathogenesis, and treatment. Endocr Rev. 2021;43:678–719.PubMedCentralCrossRef Yang Q, Ciebiera M, Bariani MV, Ali M, Elkafas H, Boyer TG, et al. Comprehensive review of uterine fibroids: developmental origin, pathogenesis, and treatment. Endocr Rev. 2021;43:678–719.PubMedCentralCrossRef
10.
Zurück zum Zitat Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124:1501–12.PubMedCrossRef Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124:1501–12.PubMedCrossRef
12.
Zurück zum Zitat Lee M, Chung Y-J, Kim H-K, Hwang H, Park JY, Shin I, et al. Estimated prevalence and incidence of uterine leiomyoma, and its treatment trend in south korean women for 12 years: a national population-based study. J Womens Health. 2021;30:1038–46.CrossRef Lee M, Chung Y-J, Kim H-K, Hwang H, Park JY, Shin I, et al. Estimated prevalence and incidence of uterine leiomyoma, and its treatment trend in south korean women for 12 years: a national population-based study. J Womens Health. 2021;30:1038–46.CrossRef
13.
Zurück zum Zitat Zimmermann A, Bernuit D, Gerlinger C, Schaefers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Womens Health. 2012;12:6.PubMedPubMedCentralCrossRef Zimmermann A, Bernuit D, Gerlinger C, Schaefers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Womens Health. 2012;12:6.PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Kim MH, Park YR, Lim DJ, Yoon KH, Kang MI, Cha BY, et al. The relationship between thyroid nodules and uterine fibroids. Endocr J. 2010;57:615–21.PubMedCrossRef Kim MH, Park YR, Lim DJ, Yoon KH, Kang MI, Cha BY, et al. The relationship between thyroid nodules and uterine fibroids. Endocr J. 2010;57:615–21.PubMedCrossRef
16.
Zurück zum Zitat Yun J, Kim CY, Son S-H, Bae C-W, Choi Y-S, Chung S-H. Birth rate transition in the Republic of Korea: trends and prospects. J Korean Med Sci. 2022;37:e304–300.PubMedPubMedCentralCrossRef Yun J, Kim CY, Son S-H, Bae C-W, Choi Y-S, Chung S-H. Birth rate transition in the Republic of Korea: trends and prospects. J Korean Med Sci. 2022;37:e304–300.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Korea Disease Control and Prevention Agency. Korea Health Statistics 2020: Korea National Health and Nutrition Examination Survey (KNHANES VIII-2). Korea Disease Control and Prevention Agency; 2022. Korea Disease Control and Prevention Agency. Korea Health Statistics 2020: Korea National Health and Nutrition Examination Survey (KNHANES VIII-2). Korea Disease Control and Prevention Agency; 2022.
18.
Zurück zum Zitat Yasui T, Hayashi K, Okano H, Kamio M, Mizunuma H, Kubota T, et al. Uterine leiomyomata: a retrospective study of correlations with hypertension and diabetes mellitus from the Japan Nurses’ Health Study. J Obstet Gynaecol. 2018;38:1128–34.PubMedCrossRef Yasui T, Hayashi K, Okano H, Kamio M, Mizunuma H, Kubota T, et al. Uterine leiomyomata: a retrospective study of correlations with hypertension and diabetes mellitus from the Japan Nurses’ Health Study. J Obstet Gynaecol. 2018;38:1128–34.PubMedCrossRef
19.
Zurück zum Zitat Lumbiganon P, Rugpao S, Phandhu-fung S, Laopaiboon M, Vudhikamraksa N, Werawatakul Y. Protective effect of depot‐medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case‐control study. BJOG. 1996;103:909–14.CrossRef Lumbiganon P, Rugpao S, Phandhu-fung S, Laopaiboon M, Vudhikamraksa N, Werawatakul Y. Protective effect of depot‐medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case‐control study. BJOG. 1996;103:909–14.CrossRef
20.
Zurück zum Zitat Sato F, Miyake H, Nishi M, Mori M, Kudo R. Early normal menstrual cycle pattern and the development of uterine leiomyomas. J Womens Health Gend Based Med. 2000;9:299–302.PubMedCrossRef Sato F, Miyake H, Nishi M, Mori M, Kudo R. Early normal menstrual cycle pattern and the development of uterine leiomyomas. J Womens Health Gend Based Med. 2000;9:299–302.PubMedCrossRef
21.
Zurück zum Zitat Hong DG, Chung MJ, Kim BS, Lee JM, Cho YL, Lee TH, et al. Risk factors related to uterine leiomyoma in korean women: a retrospective study. Clin Exp Reprod Med. 2006;33:159–70. Hong DG, Chung MJ, Kim BS, Lee JM, Cho YL, Lee TH, et al. Risk factors related to uterine leiomyoma in korean women: a retrospective study. Clin Exp Reprod Med. 2006;33:159–70.
22.
Zurück zum Zitat Yang S-H. Evaluation of risk factors for uterine myoma diagnosed by ultrasonography. J Radiol Sci Technol. 2021;44:307–13.CrossRef Yang S-H. Evaluation of risk factors for uterine myoma diagnosed by ultrasonography. J Radiol Sci Technol. 2021;44:307–13.CrossRef
23.
Zurück zum Zitat Kim O, Ahn Y, Lee HY, Jang HJ, Kim S, Lee JE, et al. The Korea Nurses’ Health Study: a prospective cohort study. J Womens Health (Larchmt). 2017;26:892–9.PubMedCrossRef Kim O, Ahn Y, Lee HY, Jang HJ, Kim S, Lee JE, et al. The Korea Nurses’ Health Study: a prospective cohort study. J Womens Health (Larchmt). 2017;26:892–9.PubMedCrossRef
24.
Zurück zum Zitat World Health Organization. The Asia-Pacific perspective: redefining obesity and its treatment. 2000. World Health Organization. The Asia-Pacific perspective: redefining obesity and its treatment. 2000.
25.
Zurück zum Zitat Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983:385–96. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983:385–96.
26.
Zurück zum Zitat Samadi AR, Lee NC, Flanders WD, Boring r JR, Parris EB. Risk factors for self-reported uterine fibroids: a case-control study. Am J Public Health. 1996;86:858–62.PubMedPubMedCentralCrossRef Samadi AR, Lee NC, Flanders WD, Boring r JR, Parris EB. Risk factors for self-reported uterine fibroids: a case-control study. Am J Public Health. 1996;86:858–62.PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Marshall LM, Spiegelman D, Goldman MB, Manson JE, Colditz GA, Barbieri RL, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril. 1998;70:432–9.PubMedCrossRef Marshall LM, Spiegelman D, Goldman MB, Manson JE, Colditz GA, Barbieri RL, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril. 1998;70:432–9.PubMedCrossRef
28.
Zurück zum Zitat Wise LA, Palmer JR, Harlow BL, Spiegelman D, Stewart EA, Adams-Campbell LL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in african-american women: a prospective study. Am J Epidemiol. 2004;159:113–23.PubMedCrossRef Wise LA, Palmer JR, Harlow BL, Spiegelman D, Stewart EA, Adams-Campbell LL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in african-american women: a prospective study. Am J Epidemiol. 2004;159:113–23.PubMedCrossRef
29.
30.
Zurück zum Zitat Faerstein E, Szklo M, Rosenshein N. Risk factors for uterine leiomyoma: a practice-based case-control study. I. African-American heritage, reproductive history, body size, and smoking. Am J Epidemiol. 2001;153:1–10.PubMedCrossRef Faerstein E, Szklo M, Rosenshein N. Risk factors for uterine leiomyoma: a practice-based case-control study. I. African-American heritage, reproductive history, body size, and smoking. Am J Epidemiol. 2001;153:1–10.PubMedCrossRef
31.
Zurück zum Zitat Templeman C, Marshall SF, Clarke CA, DeLellis Henderson K, Largent J, Neuhausen S, et al. Risk factors for surgically removed fibroids in a large cohort of teachers. Fertil Steril. 2009;92:1436–46.PubMedCrossRef Templeman C, Marshall SF, Clarke CA, DeLellis Henderson K, Largent J, Neuhausen S, et al. Risk factors for surgically removed fibroids in a large cohort of teachers. Fertil Steril. 2009;92:1436–46.PubMedCrossRef
32.
Zurück zum Zitat Velez Edwards DR, Baird DD, Hartmann KE. Association of age at menarche with increasing number of fibroids in a cohort of women who underwent standardized ultrasound assessment. Am J Epidemiol. 2013;178:426–33.PubMedPubMedCentralCrossRef Velez Edwards DR, Baird DD, Hartmann KE. Association of age at menarche with increasing number of fibroids in a cohort of women who underwent standardized ultrasound assessment. Am J Epidemiol. 2013;178:426–33.PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Kawaguchi K, Fujii S, Konishi I, Iwai T, Nanbu Y, Nonogaki H, et al. Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy. Virchows Archiv A. 1991;419:309–15.CrossRef Kawaguchi K, Fujii S, Konishi I, Iwai T, Nanbu Y, Nonogaki H, et al. Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy. Virchows Archiv A. 1991;419:309–15.CrossRef
35.
Zurück zum Zitat Reed BG, Carr BR. The normal menstrual cycle and the control of ovulation. 2015. Reed BG, Carr BR. The normal menstrual cycle and the control of ovulation. 2015.
36.
Zurück zum Zitat Marino JL, Eskenazi B, Warner M, Samuels S, Vercellini P, Gavoni N, et al. Uterine leiomyoma and menstrual cycle characteristics in a population-based cohort study. Hum Reprod. 2004;19:2350–5.PubMedCrossRef Marino JL, Eskenazi B, Warner M, Samuels S, Vercellini P, Gavoni N, et al. Uterine leiomyoma and menstrual cycle characteristics in a population-based cohort study. Hum Reprod. 2004;19:2350–5.PubMedCrossRef
37.
Zurück zum Zitat Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JT. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J (Clin Res Ed). 1986;293:359–62.PubMedCrossRef Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JT. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J (Clin Res Ed). 1986;293:359–62.PubMedCrossRef
38.
Zurück zum Zitat Parazzini F, Negri E, La Vecchia C, Chatenoud L, Ricci E, Guarnerio P. Reproductive factors and risk of uterine fibroids. Epidemiology. 1996;7:440–2.PubMedCrossRef Parazzini F, Negri E, La Vecchia C, Chatenoud L, Ricci E, Guarnerio P. Reproductive factors and risk of uterine fibroids. Epidemiology. 1996;7:440–2.PubMedCrossRef
39.
Zurück zum Zitat Parazzini F. Risk factors for clinically diagnosed uterine fibroids in women around menopause. Maturitas. 2006;55:174–9.PubMedCrossRef Parazzini F. Risk factors for clinically diagnosed uterine fibroids in women around menopause. Maturitas. 2006;55:174–9.PubMedCrossRef
40.
Zurück zum Zitat Musey VC, Collins DC, Brogan DR, Santos VR, Musey PI, Martino-Saltzman D, et al. Long term effects of a first pregnancy on the hormonal environment: estrogens and androgens. J Clin Endocrinol Metab. 1987;64:111–8.PubMedCrossRef Musey VC, Collins DC, Brogan DR, Santos VR, Musey PI, Martino-Saltzman D, et al. Long term effects of a first pregnancy on the hormonal environment: estrogens and androgens. J Clin Endocrinol Metab. 1987;64:111–8.PubMedCrossRef
41.
Zurück zum Zitat Walker CL, Cesen-Cummings K, Houle C, Baird D, Barrett JC, Davis B. Protective effect of pregnancy for development of uterine leiomyoma. Carcinogenesis. 2001;22:2049–52.PubMedCrossRef Walker CL, Cesen-Cummings K, Houle C, Baird D, Barrett JC, Davis B. Protective effect of pregnancy for development of uterine leiomyoma. Carcinogenesis. 2001;22:2049–52.PubMedCrossRef
42.
Zurück zum Zitat Bernstein L, Pike MC, Ross RK, Judd HL, Brown JB, Henderson BE. Estrogen and sex hormone-binding globulin levels in nulliparous and parous women. J Natl Cancer Inst. 1985;74:741–5.PubMed Bernstein L, Pike MC, Ross RK, Judd HL, Brown JB, Henderson BE. Estrogen and sex hormone-binding globulin levels in nulliparous and parous women. J Natl Cancer Inst. 1985;74:741–5.PubMed
43.
Zurück zum Zitat Cook JD, Walker CL. Treatment strategies for uterine leiomyoma: the role of hormonal modulation. Semin Reprod Med. New York: Thieme Medical Publishers; 2004. 105–11. Cook JD, Walker CL. Treatment strategies for uterine leiomyoma: the role of hormonal modulation. Semin Reprod Med. New York: Thieme Medical Publishers; 2004. 105–11.
44.
Zurück zum Zitat Baird DD, Dunson DB. Why is parity protective for uterine fibroids? Epidemiology. 2003;14:247–50.PubMedCrossRef Baird DD, Dunson DB. Why is parity protective for uterine fibroids? Epidemiology. 2003;14:247–50.PubMedCrossRef
45.
Zurück zum Zitat Laughlin SK, Herring AH, Savitz DA, Olshan AF, Fielding JR, Hartmann KE, et al. Pregnancy-related fibroid reduction. Fertil Steril. 2010;94:2421–3.PubMedPubMedCentralCrossRef Laughlin SK, Herring AH, Savitz DA, Olshan AF, Fielding JR, Hartmann KE, et al. Pregnancy-related fibroid reduction. Fertil Steril. 2010;94:2421–3.PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Burbank F. Childbirth and myoma treatment by uterine artery occlusion: do they share a common biology? J Am Assoc Gynecol Laparosc. 2004;11:138–52.PubMedCrossRef Burbank F. Childbirth and myoma treatment by uterine artery occlusion: do they share a common biology? J Am Assoc Gynecol Laparosc. 2004;11:138–52.PubMedCrossRef
47.
Zurück zum Zitat Chiaffarino F, Parazzini F, La Vecchia C, Marsico S, Surace M, Ricci E. Use of oral contraceptives and uterine fibroids: results from a case-control study. BJOG. 1999;106:857–60.CrossRef Chiaffarino F, Parazzini F, La Vecchia C, Marsico S, Surace M, Ricci E. Use of oral contraceptives and uterine fibroids: results from a case-control study. BJOG. 1999;106:857–60.CrossRef
48.
Zurück zum Zitat Parazzini F, Negri EVA, La Vecchia C, Fedele L, Rabaiotti M, Luchini L. Oral contraceptive use and risk of uterine fibroids. Obstet Gynecol. 1992;79. Parazzini F, Negri EVA, La Vecchia C, Fedele L, Rabaiotti M, Luchini L. Oral contraceptive use and risk of uterine fibroids. Obstet Gynecol. 1992;79.
49.
Zurück zum Zitat Wong JY, Chang P-Y, Gold EB, Johnson WO, Lee JS. Environmental tobacco smoke and risk of late-diagnosis incident fibroids in the study of Women’s Health across the Nation (SWAN). Fertil Steril. 2016;106:1157–64.PubMedPubMedCentralCrossRef Wong JY, Chang P-Y, Gold EB, Johnson WO, Lee JS. Environmental tobacco smoke and risk of late-diagnosis incident fibroids in the study of Women’s Health across the Nation (SWAN). Fertil Steril. 2016;106:1157–64.PubMedPubMedCentralCrossRef
Metadaten
Titel
Risk of uterine leiomyomata with menstrual and reproductive factors in premenopausal women: Korea nurses’ health study
verfasst von
Sihan Song
Soojin Park
Bo Mi Song
Jung Eun Lee
Chiyoung Cha
Hyun-Young Park
Publikationsdatum
01.12.2023
Verlag
BioMed Central
Erschienen in
BMC Women's Health / Ausgabe 1/2023
Elektronische ISSN: 1472-6874
DOI
https://doi.org/10.1186/s12905-023-02447-4

Weitere Artikel der Ausgabe 1/2023

BMC Women's Health 1/2023 Zur Ausgabe

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Embryotransfer erhöht womöglich Leukämierisiko der Kinder

13.05.2024 Assistierte Reproduktion Nachrichten

Reproduktionsmedizinische Techniken haben theoretisch das Potenzial, den epigenetischen Code zu verändern und somit das Krebsrisiko der Kinder zu erhöhen. Zwischen Embryotransfer und Leukämie scheint sich ein solcher Zusammenhang bestätigt zu haben.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.